Rezolute, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2022, compared with fiscal 2021. Although the request metadata says “2021 Q4,” this filing is an annual report for FY2022, not a quarterly filing.
Business context
Rezolute is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases related to chronic glucose imbalance. It has no commercial products and has not generated meaningful revenue. Its lead candidate, RZ358, is being developed for congenital hyperinsulinism (HI); RZ402 is an oral plasma kallikrein inhibitor in development for diabetic macular edema (DME).
Key financial metrics
| Metric | FY2022 / June 30, 2022 | FY2021 / June 30, 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $32.5 million | $15.0 million |
| General and administrative expense | $9.4 million | $7.9 million |
| Total operating expenses | $41.8 million | $22.9 million |
| Net loss | $41.1 million | $20.9 million |
| Basic / diluted loss per share | $(2.26) / $(2.32) | $(2.72) / $(2.72) |
| Cash used in operating activities | $39.6 million | $20.4 million |
| Cash and cash equivalents | $150.4 million | $41.0 million |
| Working capital | $149.6 million | Not clearly stated as a comparable figure |
| Total liabilities | $2.9 million | $16.5 million |
| Long-term debt | None | $14.0 million, net of discount |
Profit margins are not applicable because the company reported no revenue. Cash increased primarily through equity financings; investing cash flows were zero in both years.
Material changes versus FY2021
- Net loss increased 96% to $41.1 million, while operating expenses rose 83%. R&D expense more than doubled, reflecting clinical development, manufacturing, and staffing costs for RZ358 and RZ402.
- Operating cash use increased by $19.2 million. Cash on hand rose to $150.4 million following substantial equity financing.
- The company repaid its $15.0 million term loan on June 30, 2022, paying $16.0 million including fees. The lender’s security interest over substantially all assets was released. A separate $0.6 million exit fee remains payable only if specified change-of-control or similar events occur.
- FY2022 included a $6.5 million non-cash gain from changes in fair value of derivative liabilities, a $2.5 million underwriting discount expense tied to Class B pre-funded warrants, and a $1.8 million loss on extinguishment of debt. These items affect reported earnings and are not recurring operating performance measures.
- Common shares outstanding were 33.6 million at June 30, 2022; the filing reports 38.8 million as of September 8, 2022. The May 2022 offering issued common shares and pre-funded warrants, and a July private placement added approximately 3.2 million shares.
Development, outlook and risks
- RZ358: In the 23-patient Phase 2b RIZE study, management reported approximately 50% improvement in hypoglycemia across dose cohorts and approximately 75% at 6 mg/kg and 9 mg/kg. Time in CGM range improved 8% across doses and 16% at the top dose; management reported larger gains in a subgroup without baseline hyperglycemia. The study was open-label and small. Management said the results could enable Phase 3 and planned to complete U.S. and European regulatory discussions by the end of Q1 2023, with Phase 3 targeted for the first half of calendar 2023.
- RZ402: Phase 1 single- and multiple-dose studies showed dose-related exposure and kallikrein inhibition, and were described as generally well tolerated. Management planned to initiate a Phase 2a proof-of-concept study in Q4 2022.
- Liquidity outlook: Management said June 2022 cash plus July 2022 financing proceeds would fund currently planned activities through at least September 2023. Elsewhere, it expected existing cash to cover planned clinical activities through the first half of FY2024, while stating additional financing would be needed for longer-term requirements. These are estimates, not guarantees.
- Funding and obligations: A $5.0 million XOMA milestone is due upon dosing the first RZ358 Phase 3 patient; a $3.0 million ActiveSite milestone is due upon dosing the first RZ402 Phase 2 patient. The filing describes up to $80.5 million in aggregate clinical and regulatory milestones under these licenses, plus potential future royalties and sales-based milestones.
- Principal risks: Clinical results may not be replicated or support approval; regulatory alignment, trial enrollment, manufacturing supply, and COVID-related disruptions could delay development. The company expects continuing losses and may need additional capital. Competition, intellectual-property challenges, and future dilution are also risks.
- Controls and contingencies: Management concluded disclosure controls and internal control over financial reporting were not effective at June 30, 2022 because of a material weakness in segregation of duties; remediation was incomplete. The auditor gave an unqualified opinion on the financial statements but did not audit internal-control effectiveness. The company reported no pending or threatened lawsuits expected to have a material effect.
Most important facts for investors to verify
- RIZE’s full clinical data, study limitations, endpoint results, safety profile, and whether regulators agree the evidence supports the proposed Phase 3 design.
- Actual timing, enrollment, dose selection, endpoints, and cost of the RZ358 Phase 3 program, and whether RZ402’s Phase 2a study proceeded as planned.
- Current cash, subsequent financing, cash-burn rate, and the basis for management’s runway estimates.
- Potential dilution from pre-funded warrants, stock options, and other equity awards; confirm subsequent share counts and warrant exercises.
- Timing and conditions for license milestones, remaining debt-related exit-fee exposure, and progress in remediating the internal-control material weakness.